Table 2.

Patient characteristics PK study

	Docetaxela	Paclitaxela	Epirubicina	Doxorubicina
Total patients, n	9	20	16	22
Total cycles, n	10	25	22	27
EGA (weeks) [median (range)]	31.8 (26.1–35.0)	31.0 (16.7–35.7)	26.8 (19.0–34.0)	28.7 (15.0–36.3)
BSA (m2) [median (range)]	1.91 (1.66–2.06)	1.92 (1.74–2.27)	1.89 (1.58–2.48)	1.78 (1.56–2.49)
Dosing schedule	100 mg/m2	60 mg/m2 80 mg/m2 175 mg/m2	100 mg/m2	25 mg/m2 50 mg/m2 60 mg/m2

^a[1, 8]